VV116 exerts potent efficacy against feline infectious peritonitis.

Abstract

Feline infectious peritonitis (FIP) is a fatal disease in cats caused by feline infectious peritonitis virus (FIPV) with no officially approved antiviral therapy. In this study, we evaluated the anti-FIPV potential of VV116 and found that it potently inhibited viral replication in CRFK cells (EC= 1.57 μM). In experimental FIPV-infected cats, VV116 significantly reversed clinicopathological abnormalities, improved survival to 75%, and reduced viral loads in most organs to levels below or at the limit of detection, achieving a greater reduction compared to GS‑441524. Marked histopathological improvement was also observed in both treated groups. Together, these findings support VV116 as a promising oral candidate for the treatment of FIP and warrant further evaluation in veterinary clinical settings.